Evidence map›Paper›PMID 39942697›Full record

ArticleMolecules (Basel, Switzerland)2025

In Vitro CO-Releasing and Antioxidant Properties of Sulfonamide-Based CAI-CORMs in a H

Emanuela Berrino, Paolo Guglielmi, Fabrizio Carta, Simone Carradori, Cristina Campestre, Andrea Angeli, Francesca Arrighi, Virginia Pontecorvi, Paola Chimenti, Daniela Secci and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Gypenosides attenuate HAmerican journal of translational research · 2026
    Article
  2. Article
  3. Carbon Monoxide in an Experimental Model of Chronic Pelvic Pain Syndrome: The Effects of CORM-A1 on Pain and Anxiety-Related Behaviors.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emanuela BerrinoDepartment of Life Science, Health, and Health Professions, Link Campus University, Via del Casale di San Pio V, 44, 00165 Rome, Italy.ORCID 0000-0002-4258-0678
Paolo GuglielmiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.
Fabrizio CartaNEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0002-1141-6146
Simone CarradoriDepartment of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.ORCID 0000-0002-8698-9440
Cristina CampestreDepartment of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.ORCID 0000-0001-5870-7509
Andrea AngeliNEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0002-1470-7192
Francesca ArrighiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.ORCID 0009-0002-6449-265X
Virginia PontecorviDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.ORCID 0000-0003-3976-2291
Paola ChimentiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.ORCID 0000-0002-4395-8126
Daniela SecciDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.
Claudiu T SupuranNEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0003-4262-0323
Marialucia GalloriniDepartment of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.ORCID 0000-0002-2283-4159

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tendinopathy is often described as a complex and multifactorial condition which affects tendons. Tendon disorders are marked by a reduction in mechanical function, accompanied by pain and swelling. At the molecular level, tendinopathy leads to oxidative stress-driven inflammation, increased cell death, disruption of extracellular matrix balance, abnormal growth of capillaries and arteries, and degeneration of collagen formation. Here, we report an innovative approach to modulate oxidative stress during tendinopathy based on sulfonamide-based Carbonic Anhydrase Inhibitors-carbon monoxide releasing molecules (CAI-CORMs) hybrids endowed with dual carbon monoxide (CO) releasing activity and carbonic anhydrase (CA) inhibition. The synthesised compounds have been studied in a model of human Achilles tendon-derived cells stimulated by H

Indexed as

Achilles TendonAntioxidantsCarbonic Anhydrase InhibitorsCarbon MonoxideHydrogen PeroxideSulfonamidesCarbonic AnhydrasesCell ProliferationCollagen Type IHumansOxidative StressAntioxidantsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesCarbon MonoxideCollagen Type IHydrogen PeroxideSulfonamidescarbonic anhydrase inhibitorsCO releaseCORMsmolecular hybridsmyoglobinspectrophotometric assaytendinopathy

Identifiers

PMID39942697
PMCPMC11819963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.